Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
The U.S. Food and Drug Administration (FDA) first approved atezolizumab (Tecentriq®) in 2016, but it received additional approvals when used in combination treatments for locally advanced or metastatic triple negative breast cancer (TNBC) and small cell lung cancer (SCLC) in March 2019.
Join hundreds of oncology nursing professionals for the Oncology Nursing Society’s annual virtual conference, ONS Bridge, on September 12 and 14, 2023.